RESUMEN
BACKGROUND: Simnotrelvir is an oral 3-chymotrypsin-like protease inhibitor that has been found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential efficacy in a phase 1B trial. METHODS: In this phase 2-3, double-blind, randomized, placebo-controlled trial, we assigned patients who had mild-to-moderate coronavirus disease 2019 (Covid-19) and onset of symptoms within the past 3 days in a 1:1 ratio to receive 750 mg of simnotrelvir plus 100 mg of ritonavir or placebo twice daily for 5 days. The primary efficacy end point was the time to sustained resolution of symptoms, defined as the absence of 11 Covid-19-related symptoms for 2 consecutive days. Safety and changes in viral load were also assessed. RESULTS: A total of 1208 patients were enrolled at 35 sites in China; 603 were assigned to receive simnotrelvir and 605 to receive placebo. Among patients in the modified intention-to-treat population who received the first dose of trial drug or placebo within 72 hours after symptom onset, the time to sustained resolution of Covid-19 symptoms was significantly shorter in the simnotrelvir group than in the placebo group (180.1 hours [95% confidence interval {CI}, 162.1 to 201.6] vs. 216.0 hours [95% CI, 203.4 to 228.1]; median difference, -35.8 hours [95% CI, -60.1 to -12.4]; P = 0.006 by Peto-Prentice test). On day 5, the decrease in viral load from baseline was greater in the simnotrelvir group than in the placebo group (mean difference [±SE], -1.51±0.14 log10 copies per milliliter; 95% CI, -1.79 to -1.24). The incidence of adverse events during treatment was higher in the simnotrelvir group than in the placebo group (29.0% vs. 21.6%). Most adverse events were mild or moderate. CONCLUSIONS: Early administration of simnotrelvir plus ritonavir shortened the time to the resolution of symptoms among adult patients with Covid-19, without evident safety concerns. (Funded by Jiangsu Simcere Pharmaceutical; ClinicalTrials.gov number, NCT05506176.).
Asunto(s)
COVID-19 , Inhibidores de Proteasa de Coronavirus , Adulto , Humanos , Administración Oral , Antivirales/administración & dosificación , Antivirales/efectos adversos , Antivirales/farmacología , Antivirales/uso terapéutico , China , Proteínas M de Coronavirus/antagonistas & inhibidores , Proteínas M de Coronavirus/metabolismo , Inhibidores de Proteasa de Coronavirus/administración & dosificación , Inhibidores de Proteasa de Coronavirus/efectos adversos , Inhibidores de Proteasa de Coronavirus/farmacología , Inhibidores de Proteasa de Coronavirus/uso terapéutico , COVID-19/metabolismo , COVID-19/terapia , Tratamiento Farmacológico de COVID-19/métodos , Método Doble Ciego , Ritonavir/administración & dosificación , Ritonavir/efectos adversos , Ritonavir/farmacología , Ritonavir/uso terapéutico , SARS-CoV-2/efectos de los fármacos , Factores de Tiempo , Combinación de MedicamentosRESUMEN
Based on previous large-scale in silico screening several factor Xa inhibitors were proposed to potentially inhibit SARS-CoV-2 Mpro. In addition to their known anticoagulants activity this potential inhibition could have an additional therapeutic effect on patients with COVID-19 disease. In this study we examined the binding of the Apixaban, Betrixaban and Rivaroxaban to the SARS-CoV-2 Mpro with the use of the MicroScale Thermophoresis technique. Our results indicate that the experimentally measured binding affinity is weak and the therapeutic effect due to the SARS-CoV-2 Mpro inhibition is rather negligible.
Asunto(s)
Proteínas M de Coronavirus/antagonistas & inhibidores , Inhibidores del Factor Xa/química , SARS-CoV-2/metabolismo , Benzamidas/química , Benzamidas/metabolismo , Sitios de Unión , COVID-19/virología , Proteínas M de Coronavirus/metabolismo , Inhibidores del Factor Xa/metabolismo , Humanos , Simulación de Dinámica Molecular , Unión Proteica , Estabilidad Proteica , Pirazoles/química , Pirazoles/metabolismo , Piridinas/química , Piridinas/metabolismo , Piridonas/química , Piridonas/metabolismo , Rivaroxabán/química , Rivaroxabán/metabolismo , SARS-CoV-2/aislamiento & purificación , Tratamiento Farmacológico de COVID-19RESUMEN
Cepharanthine (CEP) is a natural biscoclaurine alkaloid of plant origin and was recently demonstrated to have anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activity. In this study, we evaluated whether natural analogues of CEP may act as potential anti-coronavirus disease 2019 drugs. A total of 24 compounds resembling CEP were extracted from the KNApSAcK database, and their binding affinities to target proteins, including the spike protein and main protease of SARS-CoV-2, NPC1 and TPC2 in humans, were predicted via molecular docking simulations. Selected analogues were further evaluated by a cell-based SARS-CoV-2 infection assay. In addition, the efficacies of CEP and its analogue tetrandrine were assessed. A comparison of the docking conformations of these compounds suggested that the diphenyl ester moiety of the molecules was a putative pharmacophore of the CEP analogues.
Asunto(s)
Antivirales/farmacología , Bencilisoquinolinas/farmacología , COVID-19/prevención & control , Preparaciones de Plantas/farmacología , SARS-CoV-2/efectos de los fármacos , Animales , Antivirales/química , Antivirales/metabolismo , Bencilisoquinolinas/química , Bencilisoquinolinas/metabolismo , COVID-19/virología , Chlorocebus aethiops , Proteínas M de Coronavirus/antagonistas & inhibidores , Proteínas M de Coronavirus/química , Proteínas M de Coronavirus/metabolismo , Evaluación Preclínica de Medicamentos/métodos , Humanos , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Preparaciones de Plantas/química , Preparaciones de Plantas/metabolismo , Unión Proteica , Conformación Proteica , SARS-CoV-2/metabolismo , SARS-CoV-2/fisiología , Stephania/química , Células VeroRESUMEN
As a part of the efforts to quickly develop pharmaceutical treatments for COVID-19 through repurposing existing drugs, some researchers around the world have combined the recently released crystal structure of SARS-CoV-2 Mpro in complex with a covalently bonded inhibitor with virtual screening procedures employing molecular docking approaches. In this context, protease inhibitors (PIs) clinically available and currently used to treat infectious diseases, particularly viral ones, are relevant sources of promising drug candidates to inhibit the SARS-CoV-2 Mpro, a key viral enzyme involved in crucial events during its life cycle. In the present perspective, we summarized the published studies showing the promising use of HIV and HCV PIs as potential repurposing drugs against the SARS-CoV-2 Mpro.
Asunto(s)
Antivirales/farmacología , Tratamiento Farmacológico de COVID-19 , Proteínas M de Coronavirus/antagonistas & inhibidores , Reposicionamiento de Medicamentos , Inhibidores de Proteasas/farmacología , SARS-CoV-2/efectos de los fármacos , Antivirales/química , Sitios de Unión , COVID-19/virología , Proteínas M de Coronavirus/química , Proteínas M de Coronavirus/genética , Proteínas M de Coronavirus/metabolismo , Humanos , Cinética , Modelos Moleculares , Terapia Molecular Dirigida , Inhibidores de Proteasas/química , Unión Proteica , Conformación Proteica en Hélice alfa , Conformación Proteica en Lámina beta , Dominios y Motivos de Interacción de Proteínas , Ensayos Clínicos Controlados Aleatorios como Asunto , SARS-CoV-2/enzimología , SARS-CoV-2/genética , TermodinámicaRESUMEN
The search for therapeutic drugs that can neutralize the effects of COVID-2019 (SARS-CoV-2) infection is the main focus of current research. The coronavirus main protease (Mpro) is an attractive target for anti-coronavirus drug design. Further, α-ketoamide is proved to be very effective as a reversible covalent-inhibitor against cysteine proteases. Herein, we report on the non-covalent to the covalent adduct formation mechanism of α-ketoamide-based inhibitor with the enzyme active site amino acids by QM/SQM model (QM = quantum mechanical, SQM = semi-empirical QM). To uncover the mechanism, we focused on two approaches: a concerted and a stepwise fashion. The concerted pathway proceeds via deprotonation of the thiol of cysteine (here, Cys145 SγH) and simultaneous reversible nucleophilic attack of sulfur onto the α-ketoamide warhead. In this work, we propose three plausible concerted pathways. On the contrary, in a traditional two-stage pathway, the first step is proton transfer from Cys145 SγH to His41 Nδ forming an ion pair, and consecutively, in the second step, the thiolate ion attacks the α-keto group to form a thiohemiketal. In this reaction, we find that the stability of the tetrahedral intermediate oxyanion/hydroxyl group plays an important role. Moreover, as the α-keto group has two faces Si or Re for the nucleophilic attack, we considered both possibilities of attack leading to S- and R-thiohemiketal. We computed the structural, electronic, and energetic parameters of all stationary points including transition states via ONIOM and pure DFT method. Additionally, to characterize covalent, weak noncovalent interaction (NCI) and hydrogen-bonds, we applied NCI-reduced density gradient (NCI-RDG) methods along with Bader's Quantum Theory of Atoms-in-Molecules (QTAIM) and natural bonding orbital (NBO) analysis.